DDInter424 DDInter122
Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile.
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Cobicistat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Cobicistat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Cobicistat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alprazolam
Cobicistat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitolisant
Cobicistat {u} may lead to a major life threatening interaction when taken with {v} Methylprednisolone
Cobicistat {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Cobicistat may cause a minor interaction that can limit clinical effects when taken with Donepezil
Cobicistat may cause a minor interaction that can limit clinical effects when taken with Doravirine
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Cobicistat may lead to a major life threatening interaction when taken with Methylprednisolone
Cobicistat may lead to a major life threatening interaction when taken with Berotralstat